礼来Zepbound效果显著，诺和诺德在哥本哈根暴跌

智通财经2025-04-22

诺和诺德股价周四在哥本哈根暴跌，原因在于其竞争对手礼来推出的一种新药Zepbound在减肥和控制血糖方面表现出与诺和诺德的重磅注射药物Ozempic相当的效果。全球糖尿病巨头诺和诺德(NVO.US)股价周四在哥本哈根暴跌，原因在于其竞争对手礼来(LLY.US)推出的一种新药Zepbound在减肥和控制血糖方面表现出与诺和诺德的重磅注射药物Ozempic相当的效果。自周四礼来公布这一利好消息后，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529336328?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-22 16:41","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2529336328","market":"us","top_or_hot":-1,"title":"礼来Zepbound效果显著，诺和诺德在哥本哈根暴跌","media":"智通财经","content":"<div>\n<p>诺和诺德股价周四在哥本哈根暴跌，原因在于其竞争对手礼来推出的一种新药Zepbound在减肥和控制血糖方面表现出与诺和诺德的重磅注射药物Ozempic相当的效果。全球糖尿病巨头诺和诺德(NVO.US)股价周四在哥本哈根暴跌，原因在于其竞争对手礼来(LLY.US)推出的一种新药Zepbound在减肥和控制血糖方面表现出与诺和诺德的重磅注射药物Ozempic相当的效果。自周四礼来公布这一利好消息后，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042216425394ddda39&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来Zepbound效果显著，诺和诺德在哥本哈根暴跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来Zepbound效果显著，诺和诺德在哥本哈根暴跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-22 16:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042216425394ddda39&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>诺和诺德股价周四在哥本哈根暴跌，原因在于其竞争对手礼来推出的一种新药Zepbound在减肥和控制血糖方面表现出与诺和诺德的重磅注射药物Ozempic相当的效果。全球糖尿病巨头诺和诺德(NVO.US)股价周四在哥本哈根暴跌，原因在于其竞争对手礼来(LLY.US)推出的一种新药Zepbound在减肥和控制血糖方面表现出与诺和诺德的重磅注射药物Ozempic相当的效果。自周四礼来公布这一利好消息后，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042216425394ddda39&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2602419157.SGD","symbol_name":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042216425394ddda39&s=b","article_id":"2529336328","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042216425394ddda39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2529336328","pubTimestamp":1745311260,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"诺和诺德股价周四在哥本哈根暴跌，原因在于其竞争对手礼来推出的一种新药Zepbound在减肥和控制血糖方面表现出与诺和诺德的重磅注射药物Ozempic相当的效果。自周四礼来公布这一利好消息后，诺和诺德股价在哥本哈根早盘交易中下跌了9.8%，跌至380克朗。其Zepbound不仅疗效媲美注射剂型，更展现出更优的耐受性和用药依从性，这对长期依赖注射给药维持疗效的诺和诺德构成双重打击。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","SG9999001176.USD":"United Global Healthcare Acc USD","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LLY":"礼来","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0079474960.USD":"联博美国增长基金A","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4532":"文艺复兴科技持仓","BK4581":"高盛持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","NVO":"诺和诺德","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0385154629.USD":"贝莱德营养科学基金A2","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2063271972.USD":"富兰克林创新领域基金","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC"},"translate_title":"Novo Nordisk plummets in Copenhagen as Lilly Zepbound works well","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"NVO":1},"content_text":"诺和诺德股价周四在哥本哈根暴跌，原因在于其竞争对手礼来推出的一种新药Zepbound在减肥和控制血糖方面表现出与诺和诺德的重磅注射药物Ozempic相当的效果。全球糖尿病巨头诺和诺德(NVO.US)股价周四在哥本哈根暴跌，原因在于其竞争对手礼来(LLY.US)推出的一种新药Zepbound在减肥和控制血糖方面表现出与诺和诺德的重磅注射药物Ozempic相当的效果。自周四礼来公布这一利好消息后，诺和诺德股价在哥本哈根早盘交易中下跌了9.8%，跌至380克朗。据了解，Ozempic、Wegovy以及礼来的Zepbound等相关药物的成功，激发了制药行业研发更易于服用、成本更低的药片的热情。礼来公司的研究给诺和诺德带来了巨大的竞争压力，导致后者市值自年初以来已缩水三分之一。更严峻的是，医药研究机构Intron Health的分析师Naresh Chouhan据此将公司2030年销售预期直接砍掉20%，并大幅下调目标价。他在研报中直言：\"礼来的突破性研究正在重塑GLP-1药物市场格局，未来口服与注射疗法的疗效标准将被重新定义。\"面对突袭，诺和诺德火速启动应对预案。该公司透露已向FDA提交申请，要求批准一款含司美格鲁肽成分的高剂量口服减肥药。这款神秘新药的活性成分，正是其明星产品Ozempic及减肥针Wegovy的核心专利成分。此外，自2019年起，诺和诺德就以Rybelsus品牌销售低剂量司美格鲁肽(Ozempic及其姊妹药物Wegovy的关键成分)药片。这场针尖对麦芒的较量背后，是千亿级减肥市场的激烈争夺。数据显示，诺和诺德和礼来生产的减肥针剂目前已创造了数十亿美元的销售额，对2020年末预测的1300亿美元的减肥药市场至关重要。值得一提的是，礼来公司公布的其口服减肥药Orforglipron三期临床试验结果表现也同样出色，该药物在减肥效果上可媲美甚至超越注射型GLP-1药物。服用Orforglipron的患者平均减轻体重7.9%，而Ozempic在最高剂量下仅使糖尿病患者减轻约6%的体重。不过，Orforglipron在降血糖方面稍弱于Ozempic。尽管如此，Orforglipron无需饮食和饮水控制，且可在一天中任何时间服用，这些优势使其在市场竞争中具有潜力。礼来的减肥注射药Zepbound长期用药研究也显示了积极结果，定期使用该药的患者三年内体重反弹通常不超过减重量的5%，且多数人反弹比例低于5%。而诺和诺德的Wegovy在一项1.7万人的研究中显示，用药三年后体重可保持稳定。值得注意的是，礼来此次并非单线突破。其Zepbound不仅疗效媲美注射剂型，更展现出更优的耐受性和用药依从性，这对长期依赖注射给药维持疗效的诺和诺德构成双重打击。市场正密切关注FDA对诺和新药的审批进程，这场关乎千亿市场的技术赛跑，已进入白热化阶段。追加内容本文作者可以追加内容哦 !","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529336328","isCrawlerRequest":true}